Patients on antipsychotics need to be regularly monitored for signs of tardive dyskinesia, a medication-induced movement disorder diagnosed when the involuntary movements persist for at least a month ...
INGREZZA showed a nearly two-fold higher VMAT2 occupancy, consistent with greater potency when compared to AUSTEDO XR (deutetrabenazine) after a single ...
Any patient on a dopamine receptor-blocking medication may develop tardive dyskinesia (TD), though most often the condition is associated with antipsychotic medications. "You would be ill-advised to ...
Danielle Nicole Larson, MD, discusses the mental health burden on patients with tardive dyskinesia, and considerations for clinicians who manage this condition.
CAPLYTA® nearly doubled the likelihood of remission at six weeks compared to placebo as an adjunctive therapy to an antidepressant based on pooled data ...
Just days after an upbeat R&D event, Neurocrine Biosciences has found itself having to report a phase 3 failure. The company’s Ingrezza (valbenazine), approved to treat certain uncontrolled movement ...
Dec 22 (Reuters) - Neurocrine Biosciences (NBIX.O), opens new tab said on Monday its drug failed to meet the main goal in a late-stage clinical trial in patients with a type of disorder that disrupts ...
Topline data were announced from a phase 3 trial evaluating valbenazine in pediatric and adult patients with dyskinetic cerebral palsy.
Welcome to the Tardive Dyskinesia Clinical Case Review, a series of case presentations by an expert in the field of tardive dyskinesia. In this video, Christoph U. Correll, MD, professor of psychiatry ...
SAN DIEGO, Dec. 22, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the efficacy, safety, and tolerability of valbenazine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback